Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480432 | 0.86 | KIF11 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4631802 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL30579341 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL5476158 | 0.82 | LMNA (0.58) | SMN1; SMN2NPC1RAB9AKDM4ELMNA | |
| SCHEMBL25459772 | 0.81 | S1PR1 (0.53) | SMN1; SMN2NPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL30085885 | 0.81 | S1PR1 (0.53) | SMN1; SMN2NPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL5479399 | 0.80 | POLB (0.47) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL3567928 | 0.78 | S1PR1 (0.56) | SMN1; SMN2NPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL31516632 | 0.78 | CYP2A6 (0.56) | SMN1; SMN2NPC1RAB9ARXFP1ALDH1A1 | |
| SCHEMBL5484106 | 0.78 | CASP3 (0.48) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014128213-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2769722-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| CN-101146789-A | Compound (I) | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | CN | disclosed |
| US-7226927-B2 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1351691-A4 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6716851-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1351691-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002047690-A1 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069239-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | SMN1; SMN2 3150/4885NPC1 2878/4885RAB9A 3348/4885 |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | SMN1; SMN2 3214/4885NPC1 3014/4885RAB9A 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.